Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage Oxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
Marketing Status approved; illicit; investigational
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 71335-0981; 67651-0304; 67651-0305; 67651-0306; 24510-140; 71335-1080; 0904-6966; 24510-130; 65162-048; 67877-625; 71335-0677; 65162-050; 0904-7180; 65162-047; 72162-1812; 67877-623; 67651-0302; 65162-049; 67651-0303; 65162-051; 24510-110; 24510-115; 71335-1023; 24510-120; 72162-1811
UNII CD35PMG570
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Impaired gastric emptying07.02.02.004--
Incoherent19.10.03.006; 17.02.08.002--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Indifference19.05.01.0040.000021%Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site hypersensitivity12.07.03.006; 10.01.03.017; 08.02.03.006--Not Available
Injury12.01.08.004--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Intentional self-injury12.01.08.036; 19.12.01.002--Not Available
Intestinal obstruction07.13.01.002--Not Available
Intracranial pressure increased17.07.02.002--Not Available
Iron deficiency anaemia14.13.02.001; 01.03.01.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Irritable bowel syndrome19.24.01.003; 07.02.04.003--Not Available
Judgement impaired19.05.01.009; 17.03.03.0050.000062%Not Available
Lacrimation increased06.08.02.004--
Laryngospasm22.04.02.002--
Learning disability19.21.05.0020.001081%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukoencephalopathy17.13.02.0030.000186%
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Liver disorder09.01.08.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.003--Not Available
Lung disorder22.02.07.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Melaena24.07.02.013; 07.12.02.004--Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 16 Pages